- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01437033
Breath Test for Chemicals (Volatile Organic Compounds)
A Pilot Study of a Breath Test for Assessment of Volatile Organic Compounds
Background:
- Some types of cancer, like cancer of the esophagus, are difficult to detect at an early stage. A possible detection method involves collecting breath samples to look for chemicals that may be signs of cancer. However, more research is needed to determine how different chemicals appear in different breath samples. This study will involve healthy volunteers.
Objectives:
- To study chemicals appearing in breath samples of healthy volunteers.
Eligibility:
- Healthy volunteers between 30 and 60 years of age.
Design:
- Participants will fast overnight (midnight to morning) and then provide two breath samples taken 5 minutes apart.
- Breath samples will be collected on days 1, 49, and 98 of the study
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Background:
Although breath tests are common for specific uses where the biomarker is highly concentrated (e .g. alcohol, urea for Helicobacter prylori infection), lower concentration compounds in the breath can also provide information on exogenous exposures and endogenous metabolic processes.
Employing standardized collection techniques and high sensitivity measurement technologies have shown that breath profiles can accurately identify people with diseases such as breast cancer and lung cancer.
Breath profiling technologies have great potential as non-invasive tools for diagnosis and risk stratification of precancerous disease as well as elucidation of the causes of cancer.
Prior to using breath profiles for these purposes it is essential to assess how much of the breath profile and which parts of the breath profile are relatively stable over a period of time.
Objectives:
The primary objective of this pilot study is to assess the intra-individual variability of breath profiles sampled over a period of 98 days.
Eligibility:
DCEG volunteers aged 30-60 years, inclusive.
Design:
Pilot study.
Five DCEG volunteers will be enrolled for this study.
We will assess breath profiles sampled in duplicate at three time periods (days 1, 49 and 98).
We will calculate a coefficients of variation (CV) to determine the proportion and parts of the breath profile which have values less than 10% when collected on the same day,49 days apart, and 98 days apart.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20892
- National Cancer Institute (NCI), 9000 Rockville Pike
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
- INCLUSION CRITERIA:
DCEG volunteers aged 30-60 years, inclusive.
EXCLUSION CRITERIA:
Aged less than 30 years. Aged 61 years or older. Individuals who identify themselves to be in any one of the following categories over the next 4 month period:
- Plan to initial a large change in their daily amount of physical activity
- Plan to make large changes to their diet (reduce caloric intake, become a vegetarian etc)
- May possibly move away from the area for a new job, sabbatical, retirement etc
- Plan to attempt to become pregnant
- Have limited availability for any reason including prolonged vacation or business travel
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Statistics of robustness (CV, ICCs)
Tijdsspanne: 98 days
|
98 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Michael B Cook, M.D., National Cancer Institute (NCI)
Publicaties en nuttige links
Algemene publicaties
- Cook MB, Dawsey SM, Diaw L, Blaser MJ, Perez-Perez GI, Abnet CC, Taylor PR, Albanes D, Virtamo J, Kamangar F. Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1966-75. doi: 10.1158/1055-9965.EPI-10-0270. Epub 2010 Jul 20.
- Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002 Jun 20;99(6):860-8. doi: 10.1002/ijc.10427. Erratum In: Int J Cancer 2002 Oct 20;101(6):599.
- Perera FP. Cancer: the big questions to address in coming years. Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):571-3. doi: 10.1158/1055-9965.EPI-11-0184. No abstract available.
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 999911243
- 11-C-N243
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Menselijke vrijwilligers
-
University of CincinnatiWervingPapillomavirus vaccins | Human Papillomavirus-virussenVerenigde Staten
-
Centre Hospitalier de CayenneVoltooidHuman Papillomavirus-virussen
-
Nutricia ResearchActief, niet wervendGroei | Tolerantie | Veiligheid | Onderwerpen die behoefte hebben aan een Human Milk Fortifier (HMF)Nederland, Frankrijk, Duitsland, Verenigd Koninkrijk
-
Hoffmann-La RocheBeëindigdOestrogeenreceptor-positief (ER+)/Human Epidermal Growth Factor Receptor (HER2)-negatief Lokaal gevorderde of gemetastaseerde borstkankerCanada, Verenigde Staten, Verenigd Koninkrijk, Australië, Duitsland
-
National Cancer Institute (NCI)Nog niet aan het wervenPlaveiselcelcarcinoom van het hoofd en de hals | Drugs therapie | Orofarynx | Human Papillomavirus-virussen | Kanker vaccinVerenigde Staten
-
Lei LiWervingEpitheliale eierstokkanker | Circulerend tumor-DNA | CA125 | DNA-methylering | Niet-invasieve diagnose | Human Epididymis Eiwit 4 | Evaluatie van beeldvorming | OverlevingsprognoseChina
-
Fundación Pública Andaluza Progreso y SaludGilead SciencesVoltooidHuman Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Co-geïnfecteerde proefpersonenSpanje
-
Lei LiWervingEpitheliale eierstokkanker | Circulerend tumor-DNA | CA125 | DNA-methylering | Niet-invasieve diagnose | Human Epididymis Eiwit 4 | Evaluatie van beeldvorming | Overlevingsprognose | ROMA-indexChina
-
National Taiwan University HospitalWervingHepatitis C-virusinfectie | Hepatitis C-virusinfectie, reactie op therapie van | Human Immunodeficiency Virus (HIV) co-infectieTaiwan